Structural studies on ribosomes of differentially macrolide-resistant
André Rivalta, Aliza Fedorenko, Alexandre Le Scornet, Sophie Thompson, Yehuda Halfon, Elinor Breiner Goldstein, Sude Çavdaroglu, Tal Melenitzky, Disha-Gajanan Hiregange, Ella Zimmerman and 3 more
Article in Life science alliance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
André RivaltaDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0001-7417-1572
Aliza FedorenkoDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
Alexandre Le ScornetDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Sophie ThompsonDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
Yehuda HalfonAstbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK.
Elinor Breiner GoldsteinDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
Sude ÇavdarogluDepartment of Emergency Medicine, Arnavutköy State Hospital, Istanbul, Turkey.
Tal MelenitzkyDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
Disha-Gajanan HiregangeDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-1291-1624
Ella ZimmermanDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
Anat BashanDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-7705-0466
Mee-Ngan Frances YapDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0003-4213-4050
Ada YonathDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel ada.yonath@weizmann.ac.il.ORCID 0000-0002-1856-6964
Funding
Evolution and consequences of multidrug resistant ribosomeR01AI150986 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI YAP, M.-N. FRANCES · 2020 to 2024
$2.3M
NIAID NIH HHS R01 AI150986
6 · The paper itself
Abstract
Antimicrobial resistance is a major global health challenge, diminishing the efficacy of many antibiotics, including macrolides. In
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Structural studies on ribosomes of differentially macrolide-resistant · full record | OpenQuestion